# NOVAGO Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novago-therapeutics

- Industry: Biotechnology
- Headquarters: Schlieren, Switzerland
- Website: www.novagotherapeutics.com/
- Total disclosed funding: $40M
- Latest round: Series B (Aug 31, 2026)
- Investors on record: 2

## About

NOVAGO Therapeutics AG specializes in developing advanced antibody therapeutics to enhance nerve growth and regeneration, focusing on spinal cord injuries and diabetic retinopathy. Founded in 2015 and headquartered in Schlieren, Switzerland,  and The company was co-founded by Prof. Martin E. Schwab and Prof. Roger Nitsch. and the Dr. Stefan Moese is the present  Chief Executive Officer of the company. NovaGo Therapeutics AG is dedicated to creating innovative therapies for nerve repair. In August  2026, NovaGo Therapeutics AG raised CHF 24 million in series B funding co-led by Neurimmune AG and Pureos Bioventures. NovaGo Therapeutics specializes in developing human antibody therapeutics aimed at enhancing nerve growth and regeneration, particularly in the context of spinal cord injuries and diabetic retinopathy. Their core product, NG004, is designed to block the Nogo-A receptor, which is known to inhibit nerve growth, thereby promoting nerve repair and functional recovery. This therapeutic approach has demonstrated efficacy in preclinical models, addressing the unmet medical need for patients suffering from spinal cord injuries, which can lead to significant loss of sensation and motor paralysis. The primary end-users of NovaGo’s products are patients affected by these debilitating conditions. The company focuses on markets across Europe and North America, leveraging its research to address critical neurological health issues in these regions.Details regarding NovaGo Therapeutics' revenue structure are not publicly disclosed. However, the company operates through direct partnerships with clinical research institutions, enabling it to conduct trials and bring its products to market. The revenue generation model is based on collaborations with healthcare providers, research institutions, and possibly licensing agreements for its therapeutics. The firm’s flagship product, NG004, plays a critical role in its business strategy, as it represents a potential breakthrough in spinal cord injury treatment and serves as a focal point for attracting investments and partnerships aimed at advancing clinical trials. Transactions are executed on a project basis, aligning with the typical practices within the biopharmaceutical industry, where partnerships and collaborations pave the way for funding and development opportunities.

The company will use the September 2026 funding to evaluate NovaGo’s lead program in a proof-of-concept study involving acute spinal cord injury patients.

## Funding rounds

- Series B, Aug 31, 2026, $30M — Neurimmune AG, Pureos Bioventures
- Series A, Jan 4, 2019, $10M — Neurimmune AG, Pureos Bioventures

## Investors

- Neurimmune AG — Series A, Series B
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series A, Series B